The Cancer Research UK "Over 50s" trial compared 5 and 2 years of tamoxifen in women with early breast cancer. Results are reported after median follow-up of 10 years. Between 1987 and 1997, 3,449 patients age 50 to 81 years with operable breast cancer who had been taking 20 mg of tamoxifen for 2 years were randomly assigned to either stop or continue for an additional 3 years, if they were alive and recurrence free. Data on recurrences, new tumors, deaths, and cardiovascular events were obtained (April 2010).
INTRODUCTION
Tamoxifen as adjuvant treatment for early breast cancer is well established and part of standard practice. Two overviews from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) provided estimates of the long-term benefit of adjuvant tamoxifen, particularly among women with estrogen receptor (ER) -positive tumors.
1,2 Among trials with approximately 10 years of follow-up, 2 or 5 years of therapy was associated with a 29% or 47% reduction in cancer recurrence and a 17% or 26% reduction in the death rate, respectively, compared with no tamoxifen. 1 These effects were seen regardless of age, menopausal status, or use of chemotherapy.
In the later review, 2 trials that directly compared approximately 5 years of tamoxifen with 1 to 2 years were combined (18,000 women in total), with a mean length of follow-up of 5 person-years. The estimated risk reductions were 15% (P Ͻ .001) for recurrence and 8% (P ϭ .01) for breast cancer mortality. Trials of tamoxifen versus no tamoxifen were also used to examine the treatment effect of 5 versus 1 to 2 years, producing similar estimates. These data have been used to guide practice, making 5 years of therapy the recommended duration.
Although aromotase inhibitors have been introduced, many patients are unsuitable or unable to tolerate them (eg, patients with bone-health problems or serious arthraglia). Therefore, tamoxifen is still widely used for women with low-risk invasive
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breast cancer (about one fifth of postmenopausal patients) and is currently the only affordable endocrine therapy in developing countries. We report long-term follow-up of one of the largest trials comparing 5 with 2 years of tamoxifen
PATIENTS AND METHODS
The Cancer Research UK "Over 50s" trial was a multicenter international randomized trial that aimed to determine whether administration of 5 years of tamoxifen (20 mg daily) was better than 2 years, in terms of recurrence and survival. 3 Patients were eligible if they were older than age 50 years and had early breast cancer confined to one breast (T1-T3, N0 or N1, and M0). Tamoxifen was prescribed as 20 mg orally each day for 2 years. At approximately 21 months after starting treatment, women were offered random assignment to either stop or continue for another 3 years, if they had no recurrence. Additional details are provided in Appendix (online only).
Patients were recruited between January 1987 and February 1997 from 71 centers in the United Kingdom, Ireland, Greece, Turkey, Belgium, Poland, and Hong Kong. Of these, 52% were postmenopausal (ie, had no menstrual period in previous 12 months). Additional details of the study design, baseline characteristics, and results of 2,937 patients recruited up to December 1994 were reported in 1996.
3 Data on recurrences, new tumors, cardiovascular (CV) events, and deaths were collected up to April 2010, including data on deaths from the National Health Service Information Centre. The main end point was eventfree survival (EFS), defined as the time from starting tamoxifen until local or distant recurrence, new tumor (in the opposite breast or elsewhere), or death, whichever occurred first. Other outcome measures were risk of recurrence (local or distant or contralateral breast cancer), death as a result of breast cancer, overall survival (OS), CV events (ie, nonfatal or fatal), and death as a result of a CV event.
RESULTS
Random assignment was performed for 3,449 patients (n ϭ 1,724 and n ϭ 1,725 in the 2-and 5-year groups, respectively). The CONSORT diagram is shown in Figure 1 . Baseline characteristics were well balanced between the groups (Appendix Table A1 , online only). The analysis was based on a total of 37,035 person-years; 25% of patients had more than 14 years of follow-up. Median follow-up was 10.1 years. There were 1,868 EFS events, 1,577 deaths, 1,103 recurrences (876 recurrences were followed by death), 755 deaths as a result of breast cancer, and 621 CV events (including 236 deaths; Table 1 ).
The hazard ratios (HRs) for 5 versus 2 years of tamoxifen were as follows: EFS, 0.89 (95% CI, 0.81 to 0.97), P ϭ .008; OS, 0.92 (95% CI, 0.84 to 1.02), P ϭ .12; risk of recurrence, 0.83 (95% CI, 0.74 to 0.94), P ϭ .003; breast cancer mortality, 0.91 (95% CI, 0.79 to 1.06), P ϭ .22; and death after recurrence, 0.86 (95% CI, 0.76 to 0.99). These represent an 11% reduction in the EFS event rate, 8% reduction in the death rate, 17% reduction in the risk of recurrence, 9% reduction in the chance of death as a result of breast cancer, and 14% reduction in the chance of death after recurrence. Figure 2 shows the Kaplan-Meier curves for EFS and recurrence. The absolute risk difference and number needed to treat are listed in Table 2 . Ten years after starting treatment, among every 100 women who received tamoxifen for 5 years, there could be 3.9 fewer EFS events and 4.5 fewer recurrences, compared with women who received tamoxifen for only 2 years. However, the effect on EFS is largely a result of the reduction in recurrence. Fifteen years after starting treatment, there could be 5.8 fewer recurrences among every 100 women administered tamoxifen for 5 years. The Kaplan-Meier curve for contralateral breast cancer is shown in Appendix Figure A1 (online only). The NOTE. One hundred fifty-eight women had no recorded recurrence but died as a result of breast cancer; in the analysis, they were treated as experiencing recurrence on date of death. Fifty-six women died as a result of unknown causes, but these deaths were assumed to be the result of breast cancer, because in this patient group, about half of all deaths resulted from this disease. The results excluding these 56 patients did not change; the hazard ratio for breast cancer mortality was 0.91 with or without them, and the absolute risk difference at 10 years was Ϫ1.4 with or without them. Abbreviation: EFS, event-free survival.
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First occurrence of any of the events listed.
risk of developing contralateral breast cancer was reduced by 30% (HR, 0.70; 95% CI, 0.48 to 1.00). OS and breast cancer mortality are shown in Figure 2 and Table 2 . Benefits were seen up to approximately 12 years, after which there was little difference between the tamoxifen groups among all women. This could be in part because some women were more likely to die as a result of other causes in the long term, which diluted an effect on breast cancer mortality. Alternatively, there could be no additional benefit of 5 years of tamoxifen with regard to these two end points after 12 years. We investigated this further by examining the hazard rate over time, which indicates the risk of an event at approximately each time point (instead of the usual cumulative rate; Appendix Fig A2, online only) . At about 10 years, there was an unexpected dip in the hazard rate for experiencing recurrence in the 2-year group (curves for 5-year group were as expected). This led to a corresponding dip at about 12 years in the hazard rate for breast cancer mortality (ie, 2-year lag between recurrence and death), where the death rate was lower than that in the 5-year group. These observations may explain why the Kaplan-Meier curves for breast cancer mortality (and in part for overall mortality) come closer together after 12 years. It is likely a spurious finding. The cumulative risk of death as a result of causes other than breast cancer was generally not different between the two groups (Appendix Fig A3,  online only) . However, examination of hazard rate plots (Appendix Fig A4, online only) indicated a lower risk of non-breast cancer death, and hence lower overall mortality risk, in the 5-year group after 15 years (largely because of CV deaths).
There was no strong evidence of an association between age (at start of tamoxifen) and EFS or OS. The EFS HRs for women age 50 to 59, 60 to 69, and 70 to 81 years were 0.79, 0.94, and 0.86, respectively (P ϭ .35 for the interaction). Corresponding OS HRs were 0.83, 0.96, and 0.92, respectively. Similarly, the effect of 5 years of tamoxifen did not differ by menopausal status. The EFS HRs were 0.87 (95% CI, 0.77 to 0.99) and 0.90 (95% CI, 0.79 to 1.02) in pre-and postmenopausal women, respectively (P ϭ .35 for the interaction). There seemed to be a long-term benefit in the youngest age group (Appendix Fig A5, online only ; P ϭ .052 for OS), but this was largely because of a reduction in CV deaths rather than deaths resulting from breast cancer.
Of the 3,449 patients, 217 were recorded as having stopped taking tamoxifen early (15 and 202 patients in the 2-and 5-year groups, Among all women, there was a nonstatistically significant reduction in the risk of CV disease and death (Appendix Fig A6, online  only) . The HR for a CV event (fatal or nonfatal) was 0.90 (95% CI, 0.77 to 1.05; P ϭ .18), and for death as a result of CV disease, the reduction was almost statistically significant at 0.79 (95% CI, 0.61 to 1.03; P ϭ .08). However, the effect was greatest in women age 50 to 59 years (Fig  3) . The P values for the interaction between age and treatment group were .11 (CV deaths) and .046 (CV event). In this age group, there was a 35% reduction in CV events (HR, 0.65; 95% CI, 0.47 to 0.88) and 59% reduction in CV deaths (HR, 0.41; 95% CI, 0.19 to 0.90). Figure 4 shows the Kaplan-Meier curves for CV events and deaths in women age 50 to 59 years. The benefit regarding CV events could be seen almost immediately, but the effect on CV deaths only occurred after approximately 9 years. Fifteen years after starting treatment, there could be 6.7 fewer women experiencing a CV event and 3.3 fewer CV deaths for every 100 women age 50 to 59 years who take tamoxifen for 5 years, compared with 2 years of treatment. Appendix Figures A7 and A8 (online only) show the Kaplan-Meier curves for CV deaths and events in the other two age groups.
DISCUSSION
The Cancer Research UK "Over 50s" trial shows that there are longterm benefits with 5 years of tamoxifen treatment, compared with 2 years. The overall proportional risk reductions for recurrence and breast cancer mortality (17% and 9%, respectively) were similar to those of the EBCTCG reviews (15% and 8%, respectively). 2 Five years of tamoxifen treatment was associated with approximately six fewer women per 100 treated experiencing recurrence 15 years later (compared with 2 years of treatment) and a significant 30% reduction in the 
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Estimated using the event rate in the 2-year tamoxifen group and the hazard ratios and 95% CIs provided in the Results section. †A negative risk difference indicates that 5 years of tamoxifen was more beneficial because there were fewer events. risk for developing a new tumor in the opposite breast. A clear benefit with regard to survival or breast cancer mortality was seen up to approximately 12 years but not afterward. However, we believe that the lack of a difference in later years is likely the result of women dying as a result of other causes and in part a spurious finding in the trial, which should be examined in other studies.
Importantly, we found a reduced risk of CV disease. This is consistent with a Swedish Breast Cancer Group trial comparing 5 with 2 years of tamoxifen, in which 299 women died as a result of CV disease (HR, 0.79; 95% CI, 0.39 to 1.00; P ϭ .047). 4 In the Over 50s trial, we observed a large number of both CV events (n ϭ 621) and CV deaths (n ϭ 236) and found the same reduction in CV deaths. However, we observed that the benefit of 5 years of tamoxifen was greatest in the group of women age 50 to 59 years. This was an exploratory analysis performed based on evidence that atherosclerotic risk increases with age, and tamoxifen can lower blood lipid levels, with studies reporting improved CV risk factors such as cholesterol, lipoprotein, apolipoprotein AI and B, and endothelial function.
5-8 It could be that older patients have higher levels of atherosclerosis, which tamoxifen is unable to reverse, but in younger patients, tamoxifen may help to slow the aging process within the blood vessels, such that those receiving 5 years of treatment benefit the most.
A protective effect against CV disease has been seen in trials comparing tamoxifen with no tamoxifen (control or placebo), such as the National Surgical Adjuvant Breast and Bowel Project B-14 trial (41 CV deaths) 9 and a trial from the Scottish Cancer Trials Breast Group (37 women with myocardial infarction). 10 In the 2005 EBCTCG meta-analysis, 2 there were a total of 120 deaths as a result of heart disease among 7,512 patients administered tamoxifen for 5 years compared with 132 deaths among 7,505 patients not administered tamoxifen (P ϭ .06). However, in the National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial for preventing breast cancer in high-risk women, the HR for all ischemic heart disease was 1.03 (95% CI, 0.79 to 1.36; 222 events).
11
The Over 50s trial had two main limitations. Because this was a relatively old trial, ER status was not measured at most centers, so we were unable to perform an analysis only in patients with ER-positive tumors. However, a large proportion of women are expected to be positive, and the results of this trial are consistent with those of other studies. The case report forms had a specific field to collect data on cardiovascular events, but details regarding type of event were not requested. It is possible that ascertainment of CV events was more complete in some studies (including ours) than others, which could explain why an association between CV disease and tamoxifen is occasionally not found. Furthermore, CV deaths were ascertained from hospitals and the national registry. However, the benefit does not seem to appear until several years later, so studies with a relatively short follow-up may not detect it.
We found three published long-term follow-up trials comparing 5 and 2 years of tamoxifen; two were much smaller than our trial. In the Italian study of adjuvant treatment in breast cancer involving 1,901 patients age 50 to 70 years (549 deaths 9 years after recruitment finished), the HR for all-cause mortality was 1.02 (95% CI, 0.86 to 1.22) . 12 The authors concluded that the benefit of 5 years was only seen in ER-positive women age 50 to 55 years 9 years after diagnosis (HR, 0.56; P ϭ .05). In our trial (1,200 deaths), the benefit with regard to OS and EFS was seen after 3 years. In the Stockholm Breast Cancer Study Group trial (796 postmenopausal women), 13 there were 402 events (recurrence, new tumor, or death) and 304 deaths after median follow-up of 18 years, with HRs as follows: EFS, 0.92 (95% CI, 0.75 to 1.12; P ϭ .38) and OS, 0.85 (95% CI, 0.68 to 1.07; P ϭ .17). Both studies probably had insufficient numbers of events to produce more precise estimates. The Swedish Breast Cancer Cooperative Group trial (n ϭ 4,175) reported mortality data after median follow-up of 10.6 years, with reductions in OS (1,480 deaths; HR, 0.81; P Ͻ .001), breast cancer mortality (792 deaths; HR, 0.84; P ϭ .013), and contralateral breast cancer incidence (138 events; HR, 0.68; P ϭ .026). 4 However, survival curves were not shown, and no long-term data on recurrence were reported. To our knowledge, therefore, the Over 50s trial is the first large randomized study of 5 versus 2 years of tamoxifen to report long-term data on recurrence, contralateral breast cancer, mortality, and both CV events and deaths (and that the effect on CV disease was largely confined to younger women).
Although treatment compliance in the 5-year group may have been as high as 88% in our trial, adherence to treatment tends to be lower in routine practice.
14 We conducted a MEDLINE literature review and found several reports of tamoxifen compliance, showing that many women stop early (Table 3) , almost half by 5 years (indicated by the two largest studies 21, 24 21 ; those with less than 80% adherence had an increased risk of death compared with those with Ն 80% adherence (HR, 1.10; 95% CI, 1.00 to 1.21).
Randomized trials of 10 versus 5 years of tamoxifen are continuing. The 2005 EBCTCG review, 2 using early data from these studies, reported a possible excess risk of non-breast cancer deaths in the 10-year group, but longer follow-up is required to properly evaluate this as well as the effect on recurrence and mortality. Interim results of the large ATLAS (Adjuvant Tamoxifen Longer Against Shorter) trial indicate that continued tamoxifen could be associated with a 12% reduction in the risk of breast cancer recurrence (presented by Richard Peto at the 30th San Antonio Breast Cancer Symposium, San Antonio, TX, December 15-17, 2007).
Trials of aromatase inhibitors (AIs) have demonstrated superior disease-free survival (DFS) compared with tamoxifen when used for 5 years. The risk of recurrence/death was reduced by 18% using letrozole in the BIG (Breast International Group) 1-98 trial 26 and by 15% using anastrozole in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial.
27 Long-term follow-up of the ATAC trial showed that the difference was maintained at 9 years; 74.2% versus 70.1% of patients were alive and disease free in the anastrozole and tamoxifen groups, respectively. Tamoxifen is associated with hot flushes, thrombotic events, and endometrial cancer, whereas AIs are associated with osteoporosis, fractures, and arthritis. 28 The BIG 1-98 trial also found a lower of risk of grade 3 to 5 cardiac adverse events in the tamoxifen group compared with that in the letrozole group. 29 Although AIs have improved efficacy in postmenopausal women, tamoxifen remains a highly effective endocrine therapy, which can also be used in premenopausal women. Furthermore, because of its low cost, tamoxifen is currently the only affordable agent in many (developing) countries, where the cost per month can range from $5 to $15. 30, 31 In the United States, the monthly cost was $40 to $100, compared with several hundred dollars for an AI. 30, 31 In the United Kingdom, the published list price of tamoxifen is £2 per month (20-mg tablets) compared with £68 for anastrozole and £66 for letrozole. 32 However, AIs will begin to go off patent in the near future, so they should become considerably cheaper.
In summary, the Over 50s trial showed that 15 years after starting 5 years of tamoxifen, there was a clear reduction in the risk of recurrence and of developing cancer in the opposite breast. Furthermore, there was a reduction in CV disease and mortality, particularly among women age 50 to 59 years. Therefore, women should be encouraged to continue with their adjuvant tamoxifen therapy for the current recommended target duration of 5 years. This study also highlights the value of collecting long-term follow-up data.
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